The New England Journal of Medicine; Hacisuleyman E, Hale C et. al.
Apr 22nd, 2021 - Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are of clinical concern. In a cohort of 417 persons who had received the second dose of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine at least 2 weeks previously, we identified 2 women with vaccine breakthrough infection. Despite evidence o...
Medrxiv Gazit S, Shlezinger R et. al.
Aug 25th, 2021 - Background Reports of waning vaccine-induced immunity against COVID-19 have begun to surface. With that, the comparable long-term protection conferred by previous infection with SARS-CoV-2 remains unclear.
https://doi.org/10.1038/s41591-021-01316-7 10.1056/NEJMoa2034577 10.1038/s41591-020-01172-x 10.1056/NEJMe2034717 10.1126/science.abe5938 10.1038/s41591-020-0869-5 10.1056/NEJMp2025631 10.1016/S2213-2600(20)30354-4
Nature Medicine; Levine-Tiefenbrun M, Yelin I et. al.
Mar 31st, 2021 - Beyond their substantial protection of individual vaccinees, coronavirus disease 2019 (COVID-19) vaccines might reduce viral load in breakthrough infection and thereby further suppress onward transmission. In this analysis of a real-world dataset of positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test results after in...
https://doi.org/10.1097/MCP.0000000000000774 10.1111/tbed.13707. 10.1186/s40779-020-00240-0 10.1016/j.cub.2020.03.063 10.3390/ani11010164 10.1007/s11259-021-09787-2 10.1038/s41467-020-17436-6 10.1016/j.jhin.2020.12.022.
Current Opinion in Pulmonary Medicine; Hui DS, Zumla A et. al.
Mar 5th, 2021 - Severe acute respiratory syndrome-coronaviruses-2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), emerged as a new zoonotic pathogen of humans at the end of 2019 and rapidly developed into a global pandemic. Over 106 million COVID-19 cases including 2.3 million deaths have been reported to the WHO as of February 9, 2021. This review examines th...
Jan 1st, 2021 - This report describes COVID-19 outbreaks associated with ...
Apr 21st, 2021 - Real-world risks of developing COVID-19 infection and illness after full vaccination are coming into focus as more reports come in with hard numbers. Just on Wednesday, three such publications appeared: Collectively, these reports provide more assurance that the phase III trial results with the Pfizer/BioNTech and Moderna vaccines did not exaggerate their effectiveness and that breakt...
Infectious Diseases (London, England); Ioannou P, Karakonstantis S et. al.
Jun 29th, 2021 - Vaccination against COVID-19 is among the most effective measures to stop the spread of the disease. However, acceptance of vaccination against COVID-19 among HCWs has not been universal and emergence of new variants with increased transmissibility, reduced neutralization by BNT162b2 vaccine-elicited sera and ability to cause breakthrough infections in vaccinated ind...
The Journal of Clinical Investigation; Duerr R, Dimartino D et. al.
Aug 11th, 2021 - The efficacy of COVID-19 mRNA vaccines is high, but breakthrough infections still occur. We compared the SARS-CoV-2 genomes of 76 breakthrough cases after full vaccination with BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna), or JNJ-78436735 (Janssen) to unvaccinated controls (February-April 2021) in metropolitan New York, including their phylogenetic relationship, d...
Clinical Infectious Diseases : an Official Publication Of... McEwen AE, Cohen S et. al.
Jun 25th, 2021 - Across 20 vaccine breakthrough cases detected at our institution, all 20 (100%) infections were due to variants of concern (VOC) and had a median Ct of 20.2 (IQR=17.1-23.3). When compared to 5174 contemporaneous samples sequenced in our laboratory, VOC were significantly enriched among breakthrough infections (p < .05).
BMC Medicine; Farinholt T, Doddapaneni H et. al.
Oct 2nd, 2021 - This study aims to identify the causative strain of SARS-CoV-2 in a cluster of vaccine breakthroughs. Vaccine breakthrough by a highly transmissible SARS-CoV-2 strain is a risk to global public health. Nasopharyngeal swabs from suspected vaccine breakthrough cases were tested for SARS-CoV-2 (severe acute respiratory...
Infection Control and Hospital Epidemiology; Geysels D, Van Damme P et. al.
Jul 23rd, 2021 - SARS-CoV-2 vaccine breakthrough infections among healthcare workers in a large Belgian hospital network.|2021|Geysels D,Van Damme P,Verstrepen W,Bruynseels P,Janssens B,|
MMWR. Morbidity and Mortality Weekly Report; Brown CM, Vostok J et. al.
Aug 6th, 2021 - During July 2021, 469 cases of COVID-19 associated with multiple summer events and large public gatherings in a town in Barnstable County, Massachusetts, were identified among Massachusetts residents; vaccination coverage among eligible Massachusetts residents was 69%. Approximately three quarters (346; 74%) of cases occurred in fully vaccinated persons (those who had completed a 2-dose course ...
Medrxiv Farinholt T, Doddapaneni H et. al.
High numbers of global SARS-CoV-2 infections have led to the emergence of variants, notably Alpha variant (B.1.1.7 UK), Beta (B.1.351 S. Africa), Gamma (P.1 Brazil), Epsilon (B.1.429 California), Iota (B.1.526 New York) and now, Delta and Kappa (B.1.617.2 and B.1.617.1 India). Each of these strains gained advantageous mutations to become a dominant strain, e.g., Iota first discovered November 2...
Journal of Medical Virology; Mutnal MB, Johnson S et. al.
Oct 2nd, 2021 - As surges in the COVID-19 pandemic have continued worldwide, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has mutated, spawning several new variants, and impacting, to various degrees, transmission, disease severity, diagnostics, therapeutics, and natural and vaccine-induced immunity. Baylor Scott & White Health has implemented, a...
Medrxiv Musser JM, .
Genetic variants of SARS-CoV-2 have repeatedly altered the course of the COVID-19 pandemic, and disease in individual patients. Delta variants (B.1.617.2, AY.2, and AY.3) are now the focus of international concern because they are causing widespread COVID-19 disease globally. Vaccine breakthrough cases caused by SARS-CoV-2 variants also are of co...
The New England Journal of Medicine; Bergwerk M, Gonen T et. al.
Jul 29th, 2021 - Despite the high efficacy of the BNT162b2 messenger RNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), rare breakthrough infections have been reported, including infections among health care workers. Data are needed to characterize these infections and define correlates of breakthrough an...
The New England Journal of Medicine; Heath PT, Galiza EP et. al.
Jul 1st, 2021 - Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that contains the full-length spike glycoprotein of the prototype strain plus Matrix-M adjuvant, showed that the vaccine was safe and associated with a robust immune ...
The New England Journal of Medicine; Shinde V, Bhikha S et. al.
May 6th, 2021 - The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants threatens progress toward control of the coronavirus disease 2019 (Covid-19) pandemic. In a phase 1-2 trial involving healthy adults, the NVX-CoV2373 nanoparticle vaccine had an acceptable safety profile and was associated with strong neutralizing-antibody and ...
Journal of Medical Virology; Dash GC, Subhadra S et. al.
Oct 9th, 2021 - In this study, we attempted to record the breakthrough cases reported through passive and voluntary reporting at various healthcare facilities from different districts of Odisha, their clinical presentation, requirement of hospitalization postinfection, and antibody titer against spike antigen. Nasopharyngeal swab and serum samples alongwith demographic, clinical presentation and require...
Lancet (London, England); Tartof SY, Slezak JM et. al.
Oct 8th, 2021 - Vaccine effectiveness studies have not differentiated the effect of the delta (B.1.617.2) variant and potential waning immunity in observed reductions in effectiveness against SARS-CoV-2 infections. We aimed to evaluate overall and variant-specific effectiveness of BNT162b2 (tozinameran, Pfizer-BioNTech) against SARS-CoV-2 infections and COVID-19-related hospi...